

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **GRANT OF SHARE OPTIONS**

This announcement is made by Peijia Medical Limited (the “**Company**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors (the “**Board**”) of the Company hereby announces that on December 7, 2021, the Company granted share options (the “**Share Option(s)**”) to certain employees (the “**Grantee(s)**”) to subscribe for a total of 7,801,386 ordinary shares of the Company (the “**Share(s)**”), subject to and upon the terms and conditions of the share option scheme adopted by the Company on April 28, 2020 (the “**Share Option Scheme**”). Details of the Share Options granted are set out as follows:

Date of grant:	December 7, 2021 (the “ <b>Date of Grant</b> ”)
Exercise price of the Share Options granted:	HK\$15.97 per Share (representing the highest of (i) HK\$15.97, being the average of the closing prices of the Shares as stated in the daily quotations sheet by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (ii) HK\$15.26, being the closing price of the Shares as stated in the daily quotations sheet by the Stock Exchange on the Date of Grant)  (subject to adjustments under the terms of the Share Option Scheme in accordance with Rule 17.03(13) of the Listing Rules).
Number of Share Options granted:	7,801,386 Share Options (each Share Option shall entitle the Grantees to subscribe for one Share)
Closing price of the Shares on the Date of Grant:	HK\$15.26 per Share

Validity period of the Share Options: The Share Options are valid for a period of 10 years from December 7, 2021 to December 6, 2031 (both days inclusive).

Vesting dates of the Share Options: Among the 7,801,386 Share Options, the vesting dates are one of the followings as specified in the grant letters:

- (i) the Share Options shall become vested in three period (a) immediately and shall be exercisable at any time until December 31, 2022; (b) from January 1, 2023 and shall be exercisable at any time during the period commencing on January 1, 2023 and ending on December 31, 2024; and (c) from January 1, 2025 and shall be exercisable at any time during the period commencing on January 1, 2025 and ending on December 31, 2025;
- (ii) the Share Options shall become vested in three period (a) immediately and shall be exercisable at any time until June 30, 2023; (b) from July 1, 2023 and shall be exercisable at any time during the period commencing on July 1, 2023 and ending on June 30, 2025; and (c) from July 1, 2025 and shall be exercisable at any time during the period commencing on July 1, 2025 and ending on June 30, 2026;
- (iii) the Share Options shall become vested in three period (a) from January 1, 2022 and shall be exercisable at any time during the period commencing on January 1, 2022 and ending on December 31, 2023; (b) from January 1, 2024 and shall be exercisable at any time during the period commencing on January 1, 2024 and ending on December 31, 2025; and (c) from January 1, 2026 and shall be exercisable at any time during the period commencing on January 1, 2026 and ending on December 31, 2026; and
- (iv) other vesting dates subject to the grant letters of the respective Grantees.

The number of Share Options to be vested in each vesting period for each Grantee is subject to his or her respective grant letters.

The exercise of the Share Options by the Grantees is conditional upon the fulfilment of certain performance targets relating to the Group. The performance targets have been determined by the Board and is specified in the respective grant letters of each Grantee.

None of the Grantees is a director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined in the Listing Rules) as at the date of this announcement.

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, December 7, 2021

*As at the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.*